BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1901494)

  • 1. Towards the development of improved thrombolytic agents.
    Lijnen HR; Collen D
    Br J Haematol; 1991 Mar; 77(3):261-6. PubMed ID: 1901494
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombolytic therapy.
    Collen D; Lijnen HR
    Ann N Y Acad Sci; 1991; 614():259-69. PubMed ID: 1902640
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biochemical, pharmacologic and clinical properties of new thrombolytic agents].
    Gulba DC
    Internist (Berl); 1996 Jun; 37(6):552-66. PubMed ID: 8767988
    [No Abstract]   [Full Text] [Related]  

  • 4. Can plasminogen activators be improved?
    Haber E
    Circulation; 1990 Nov; 82(5):1874-6. PubMed ID: 2121386
    [No Abstract]   [Full Text] [Related]  

  • 5. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombolytic therapy].
    Matsuda T
    Nihon Rinsho; 1998 Oct; 56(10):2577-81. PubMed ID: 9796322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombolytic therapy in acute myocardial infarct].
    Bode C; Baumann H; von Hodenberg E; Kübler W
    Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
    [No Abstract]   [Full Text] [Related]  

  • 8. [Fibrinolytic therapy in ischemic brain infarct].
    Del Zoppo GJ; Hacke W
    Dtsch Med Wochenschr; 1987 Apr; 112(15):603-8. PubMed ID: 3104001
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
    Czyrski J
    Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
    Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
    Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 14. New thrombolytic drugs in acute myocardial infarction: theoretical and practical considerations.
    Verstraete M
    Circulation; 1987 Aug; 76(2 Pt 2):II31-8. PubMed ID: 3111745
    [No Abstract]   [Full Text] [Related]  

  • 15. Remaining perspectives of mutant and chimeric plasminogen activators.
    Lijnen HR; Collen D
    Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-chain urokinase-type plasminogen activator: mechanism of action and thrombolytic properties.
    Lijnen HR; Stump DC; Collen DC
    Semin Thromb Hemost; 1987 Apr; 13(2):152-9. PubMed ID: 3114883
    [No Abstract]   [Full Text] [Related]  

  • 17. New thrombolytic drugs.
    Thomson A
    Aust N Z J Med; 1999 Jun; 29(3):433-5. PubMed ID: 10868516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New directions in thrombolytic therapy.
    Toombs CF
    Curr Opin Pharmacol; 2001 Apr; 1(2):164-8. PubMed ID: 11714091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.